がん治療 - 世界市場の考察、競合情勢、市場予測（2030年）

世界のがん治療の市場規模は、2020年に1,552億3,000万米ドル、2030年までに2,663億1,000万米ドルに達し、2024年～2030年の予測期間にCAGRで9.12％の成長が見込まれます。市場は、がん治療需要の増加に寄与しているさまざまながんの流行や、乳がんなどの特定のがん種において年齢が発症に重要な役割を果たすことから、老年人口の増加といった要因の存在により、前向きな市場成長を示しています。さらに、より顕著な治療効果をもたらす精密医療の進歩により、標的療法の開発に注目が集まっていることも、新製品ががん治療の規制当局の承認を得ていることから、がん治療市場をさらに牽引しています。

がん治療の市場力学

がん治療市場の主な促進要因の1つは、がんの罹患率の急増です。International Agency for Research on Cancerが実施したGLOBOCAN調査によると、2020年に世界で新たに1,930万人のがん患者が発生し、約1,000万人が死亡したと推定されています。また、上記の資料によれば、2020年におけるがん関連死の主な原因は肺がんが180万人ともっとも多く、次いで大腸がん（9.4％）、肝臓がん（8.3％）、胃がん（7.7％）、女性乳がん（6.9％）となっています。がんは身体を衰弱させる疾患であるため、がん細胞を治療するためには大規模な治療が必要です。外科手術、化学療法、放射線療法などのさまざまな治療法ががん治療に採用されているのは、がん治療において治癒効果だけでなく緩和効果も得られるという利点があるからです。このように、さまざまな種類のがん治療に対するニーズの高まりは、さまざまな種類の治療に反応する可能性のあるがんの罹患率の増加によるものと考えられます。したがって、前述の要因はすべて、がん治療への需要の拡大に寄与し、結果として世界のがん治療市場の成長を後押しすると予測されます。

がん治療市場の成長を後押ししているもう1つの特徴は、がん治療における精密医療の人気の高まりです。例えば、精密医療は、診断から投与可能な治療法の考案まで、がん治療のさまざまな段階で医師を支援します。腫瘍のタイピングは精密医療における主要分野の1つであり、腫瘍の発生や治療抵抗性に関与する遺伝子の種類を特定することで、予後を改善する標的治療の開発に道を開きます。

さらに、RNAシーケンシングや次世代シーケンシングのような新技術の開発は、予知および予後の分子変化の検出を向上させ、より個別化されたアプローチを推進する上で極めて重要です。例えば、米国を拠点とするNational Cancer Institute（NCI）は、がん治療に関する精密医療プログラムに多額の投資を行っています。現在進行中のNCIプログラムには、NCI Translational and Therapeutic Studies、NCI Immunology and Immunotherapy Research、NCI Genomics and Cancer Biology Researchなどがあります。このことは、今後数年間で市場に登場する可能性のある多数の治療法を示しており、予測期間のがん治療市場の成長をさらに後押しします。

しかし、骨量の減少などのさまざまながん治療に伴う潜在的な副作用や、特に低中所得国におけるがん治療のコストが、がん治療市場の成長にとっての課題となる可能性があります。

がん治療市場は、COVID-19の拡大を抑制するための対策の実施によってマイナスの影響を受けました。COVID-19パンデミックによって生じた緊急事態に対応するため、その他のすべての医療専門分野では患者数の減少が見られました。例えば、Cancer Research UKによると、英国だけでも、ロックダウン初期に緊急の肺がんの紹介は最大75％減少しました。これは症例の減少とは関係なく、緊急に必要な診断を求め、それを得る人が減ったということです。残念ながら、こうした動向は世界各国で顕著でした。とはいえ、がん医療を変革する戦略の考案により、がん治療市場は回復基調にあり、それによって2024年～2030年の予測期間におけるがん治療市場の将来の見通しが示されています。

当レポートでは、世界のがん治療市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 がん治療市場レポートのイントロダクション

第2章 がん治療市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価
• 財務ベンチマーク

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 がん治療市場の主な要因の分析

• がん治療市場の促進要因
• がん治療市場の抑制要因と課題
• がん治療市場の機会

第5章 がん治療市場のポーターのファイブフォース分析

第6章 がん治療市場に対するCOVID-19の影響分析

第7章 がん治療市場のレイアウト

• 治療タイプ別
  • 化学療法
  • 放射線療法
  • ホルモン療法
  • 標的療法
  • その他
• がんタイプ別
  • 乳がん
  • 肺がん
  • 前立腺がん
  • 血液がん
• エンドユーザー別
  • 病院
  • 専門クリニック
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 がん治療市場における：世界の企業シェア分析 - 主要3～5社

第9章 がん治療市場の企業と製品のプロファイル

• GlaxoSmithKline
• Eli Lilly & Company
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• Amgen Inc.
• Sanofi
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• AstraZeneca
• Bristol Myers Squibbs
• Gilead Sciences, Inc.
• Janssen Global Services, LLC
• Elekta AB
• Varian Medical Systems, Inc (Siemens Healthineers AG)
• Accuray Incorporated
• Pyrexar Medical
• Eckert & Ziegler
• IBA
• Panacea Medical Technologies Pvt. Ltd

第10章 KOLの見解

第11章 プロジェクトアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Cancer Therapy Market
• Table 3: Cancer Therapy Market in Global (2018-2030)
• Table 4: Cancer Therapy Market in Global by Therapy Type (2018-2030)
• Table 5: Cancer Therapy Market in Global by Cancer Type (2018-2030)
• Table 6: Cancer Therapy Market in Global by End User (2018-2030)
• Table 7: Cancer Therapy Market in Global by Geography (2018-2030)
• Table 8: Cancer Therapy Market in North America (2018-2030)
• Table 9: Cancer Therapy Market in North America by Therapy Type (2018-2030)
• Table 10: Cancer Therapy Market in North America by Cancer Type (2018-2030)
• Table 11: Cancer Therapy Market in North America by End User (2018-2030)
• Table 12: Cancer Therapy Market in North America by Country (2018-2030)
• Table 13: Cancer Therapy Market in the US (2018-2030)
• Table 14: Cancer Therapy Market in Canada (2018-2030)
• Table 15: Cancer Therapy Market in Mexico (2018-2030)
• Table 16: Cancer Therapy Market in Europe (2018-2030)
• Table 17: Cancer Therapy Market in Europe by Therapy Type (2018-2030)
• Table 18: Cancer Therapy Market in Europe by Cancer Type (2018-2030)
• Table 19: Cancer Therapy Market in Europe by End User (2018-2030)
• Table 20: Cancer Therapy Market in Europe by Country (2018-2030)
• Table 21: Cancer Therapy Market in France (2018-2030)
• Table 22: Cancer Therapy Market in Germany (2018-2030)
• Table 23: Cancer Therapy Market in the United Kingdom (2018-2030)
• Table 24: Cancer Therapy Market in Italy (2018-2030)
• Table 25: Cancer Therapy Market in Spain (2018-2030)
• Table 26: Cancer Therapy Market in Russia (2018-2030)
• Table 27: Cancer Therapy Market in Rest of Europe (2018-2030)
• Table 28: Cancer Therapy Market in APAC (2018-2030)
• Table 29: Cancer Therapy Market in APAC by Therapy Type (2018-2030)
• Table 30: Cancer Therapy Market in APAC by Cancer Type (2018-2030)
• Table 31: Cancer Therapy Market in APAC by End User (2018-2030)
• Table 32: Cancer Therapy Market in APAC by Country (2018-2030)
• Table 33: Cancer Therapy Market in China (2018-2030)
• Table 34: Cancer Therapy Market in Japan (2018-2030)
• Table 35: Cancer Therapy Market in India (2018-2030)
• Table 36: Cancer Therapy Market in Australia (2018-2030)
• Table 37: Cancer Therapy Market in South Korea (2018-2030)
• Table 38: Cancer Therapy Market in Rest of APAC (2018-2030)
• Table 39: Cancer Therapy Market in Rest of World (2018-2030)
• Table 40: Cancer Therapy Market in RoW by Therapy Type (2018-2030)
• Table 41: Cancer Therapy Market in RoW by Cancer Type (2018-2030)
• Table 42: Cancer Therapy Market in RoW by End User (2018-2030)
• Table 43: Cancer Therapy Market in RoW by Region (2018-2030)
• Table 44: Cancer Therapy Market in Middle East (2018-2030)
• Table 45: Cancer Therapy Market in Africa (2018-2030)
• Table 46: Cancer Therapy Market in South America (2018-2030)

List of Figures

Figures 1: Competitive Analysis

Figures 2: COVID-19 Impact Analysis on Cancer Therapy Market

Figures 3: Cancer Therapy Market in Global (2018-2030)

Figures 4: Cancer Therapy Market in Global by Therapy Type (2018-2030)

Figures 5: Cancer Therapy Market in Global by Cancer Type (2018-2030)

Figures 6: Cancer Therapy Market in Global by End User (2018-2030)

Figures 7: Cancer Therapy Market in Global by Geography (2018-2030)

Figures 8: Cancer Therapy Market in North America (2018-2030)

Figures 9: Cancer Therapy Market in North America by Therapy Type (2018-2030)

Figures 10: Cancer Therapy Market in North America by Cancer Type (2018-2030)

Figures 11: Cancer Therapy Market in North America by End User (2018-2030)

Figures 12: Cancer Therapy Market in North America by Country (2018-2030)

Figures 13: Cancer Therapy Market in the US (2018-2030)

Figures 14: Cancer Therapy Market in Canada (2018-2030)

Figures 15: Cancer Therapy Market in Mexico (2018-2030)

Figures 16: Cancer Therapy Market in Europe (2018-2030)

Figures 17: Cancer Therapy Market in Europe by Therapy Type (2018-2030)

Figures 18: Cancer Therapy Market in Europe by Cancer Type (2018-2030)

Figures 19: Cancer Therapy Market in Europe by End User (2018-2030)

Figures 20: Cancer Therapy Market in Europe by Country (2018-2030)

Figures 21: Cancer Therapy Market in France (2018-2030)

Figures 22: Cancer Therapy Market in Germany (2018-2030)

Figures 23: Cancer Therapy Market in the United Kingdom (2018-2030)

Figures 24: Cancer Therapy Market in Italy (2018-2030)

Figures 25: Cancer Therapy Market in Spain (2018-2030)

Figures 26: Cancer Therapy Market in Russia (2018-2030)

Figures 27: Cancer Therapy Market in Rest of Europe (2018-2030)

Figures 28: Cancer Therapy Market in APAC (2018-2030)

Figures 29: Cancer Therapy Market in APAC by Therapy Type (2018-2030)

Figures 30: Cancer Therapy Market in APAC by Cancer Type (2018-2030)

Figures 31: Cancer Therapy Market in APAC by End User (2018-2030)

Figures 32: Cancer Therapy Market in APAC by Country (2018-2030)

Figures 33: Cancer Therapy Market in China (2018-2030)

Figures 34: Cancer Therapy Market in Japan (2018-2030)

Figures 35: Cancer Therapy Market in India (2018-2030)

Figures 36: Cancer Therapy Market in Australia (2018-2030)

Figures 37: Cancer Therapy Market in South Korea (2018-2030)

Figures 38: Cancer Therapy Market in Rest of APAC (2018-2030)

Figures 39: Cancer Therapy Market in Rest of World (2018-2030)

Figures 40: Cancer Therapy Market in RoW by Therapy Type (2018-2030)

Figures 41: Cancer Therapy Market in RoW by Cancer Type (2018-2030)

Figures 42: Cancer Therapy Market in RoW by End User (2018-2030)

Figures 43: Cancer Therapy Market in RoW by Region (2018-2030)

Figures 44: Cancer Therapy Market in Middle East (2018-2030)

Figures 45: Cancer Therapy Market in Africa (2018-2030)

Figures 46: Cancer Therapy Market in South America (2018-2030)

Figures 47: Market Drivers

Figures 48: Market Barriers

Figures 49: Marker Opportunities

Figures 50: PORTER'S Five Force Analysis

Cancer Therapy Market By Therapy Type (Chemotherapy, Radiation Therapy, Hormonal Therapy, Targeted Therapy, And Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, And Others), By End User (Hospitals, Specialty Clinics, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to rising prevalence of various cancers such as lung and breast cancers and growing demand for targeted therapies for cancer treatment

Global cancer therapy market was valued at USD 155.23 billion in 2020, growing at a CAGR of 9.12% during the forecast period from 2024 to 2030, in order to reach USD 266.31 billion by 2030. The cancer therapy market is witnessing a positive market growth owing to the factors such as rising prevalence of various cancers which are contributing in the growing demand for cancer treatment, and presence of factors like increasing aging population wherein age plays a key role in cancer development in certain cancer types namely breast cancer. Moreover, the growing focus on developing targeted therapies due to advancements in precision medicine to provide a more pronounced therapeutic effect is further driving the cancer therapy market as new products are gaining regulatory approvals for cancer treatment.

Cancer Therapy Market Dynamics:

One of the key aspects driving the cancer therapy market can be attributed to the surge in cancer incidence. The GLOBOCAN study conducted by the International Agency for Research on Cancer mentioned that in 2020, an estimated number of 19.3 million new cancer cases and approximately 10.0 million cancer deaths were reported globally. The source mentioned above also stated that in 2020, lung cancer was the main cause accounting for the highest number (1.8 million) of cancer-related deaths followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Cancer, being a debilitating disease, requires extensive treatment in order to treat cancerous cells. Various therapies such as surgery, chemotherapy, and radiation therapy are employed in cancer treatment due to the benefits associated with them in terms of providing curative as well as palliative effect in cancer treatment. Thus, the growing need for cancer therapy of various types can be attributed to the increasing cancer incidence which may respond to different therapy types. Therefore, all the aforementioned factors are projected to contribute growing demand for cancer therapy, ultimately boosting the growth of the global cancer therapy market.

Another aspect that is aiding in the growth of the cancer therapy market is the growing popularity of precision medicine in cancer treatment. For instance, precision medicine enables doctors in various stages of cancer treatment right from diagnosis to devising the type of therapy that can be administered. Tumor typing is one the key areas in precision medicine which helps in identifying the type of gene/s that play a role in tumor development as well as therapy resistance thereby paving the way for the development of targeted therapy to achieve better prognostic outcomes.

Furthermore, the development of newer technologies such as RNA sequencing and next generation sequencing have been monumental in driving a more personalized approach with improvements in detecting predictive and prognostic molecular alterations. For instance, the National Cancer Institute (NCI) based in the United States has heavily invested in precision medicine programs pertaining to cancer treatment. A few of the ongoing NCI programs include NCI Translational and Therapeutic Studies, NCI Immunology and Immunotherapy Research, NCI Genomics and Cancer Biology Research among others. This indicates the plethora of potential therapies that may reach the market in coming years, further boosting the growth of cancer therapy market during the forecast period.

However, potential side-effects associated with different cancer therapies such as loss of bone mass and cost of cancer therapies especially in low- and middle-income countries may prove to be challenging factors for cancer therapy market growth.

The cancer therapy market was negatively impacted by the implementation of measures to curb the spread of the COVID-19 infection. In order to cater to the exigency created by the COVID-19 pandemic, all other medical specialties witnessed a reduction in patient load. For instance, according to Cancer Research UK, in the UK alone, for example, urgent lung cancer referrals fell by up to 75% during the first lockdown. This did not correlate to the decrease in cases, but that fewer people sought and obtained the diagnosis they urgently need. Unfortunately, these trends were prominent across countries around the globe. Nevertheless, the market for cancer therapy is on a period of recovery owing to devising of strategies to transform cancer care thereby presenting a future outlook for cancer therapy market during the forecast period from 2024-2030.

Cancer Therapy Market Segment Analysis:

Cancer Therapy Market by Therapy Type (Surgery, Chemotherapy, Radiation Therapy, Hormonal Therapy, Targeted Therapy, and Others), by Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, and Others), by End User (Hospitals, Specialty Clinics, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the therapy type segment of the cancer therapy market, the chemotherapy category is estimated to register significant share in market revenue during the forecast period (2024-2030). This can be attributed to the advantages associated with chemotherapy. Chemo is considered a systemic treatment because in this, the drug travels throughout the body, and also targets cancer cells that have metastasized to parts of the body far away from the original tumor. This makes chemotherapy different than other localized cancer therapies such as surgery and radiation. Furthermore, often it is conducted in combination with other therapies such as surgery in events to reduce the size of the tumor before removing it surgically.

Therefore, considering the advantages associated with chemotherapy, this therapy category is expected to witness a considerable growth eventually contributing the overall growth of the global cancer therapy market in the forecast period.

North America is expected to dominate the overall Cancer Therapy Market:

Among all the regions, North America is estimated to amass the largest revenue share in the global cancer therapy market. This can be ascribed to the high prevalence of cancers, and a supportive regulatory environment among other factors in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments are also expected to aid in the cancer therapy market growth in this region.

One of the key supporting factors for the growth of the North America cancer therapy market is the increasing prevalence of cancers in the United States. As per the figures mentioned by the American Cancer Society, in 2022, it was estimated that 1.9 million new cancer cases would have been diagnosed in the United States. The data provided by the Centers for Disease Control and Prevention (2023), in 2018, 1,708,921 new cases of cancers were reported. For instance, the American Cancer Society estimates that in 2022, approximately 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States. Therefore, the increasing incidence of cancers such as breast cancer in the country is expected to further drive the demand for cancer therapy such as radiation, chemotherapy, targeted therapy, thereby contributing in the growth of the United States cancer therapy market as well the overall growth of the North America cancer therapy market.

Furthermore, due to growing demand for targeted therapies in cancer treatment and extensive research and development in translation research leading to the development of new therapies as well as product approvals for the same. For instance, in September 2022, Health Canada approved LUMAKRAS(TM) (sotorasib) - the first and only targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. Similarly, in May 2020, the US Food and Drug Administration granted regulatory approval for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

Thus, such product development activities along with other stimulating factors such as the presence of a robust healthcare system and insurance coverage further drive the demand for cancer therapy in the North American region.

Cancer Therapy Market Key Players:

Some of the key market players operating in the cancer therapy market includes GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd.and others.

Recent Developmental Activities in Cancer Therapy Market:

In October 15, 2022, the US FDA approved atezolizumab (Tecentriq) by Genentech, Inc. for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).

In August 2022, Bristol Myers Squibbs received the conditional marketing authorization for Abecma (idecabtagene vicleucel) by the European Commission for the treatment of adult patients with relapsed and refractory multiple myeloma. It is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.

In June 2022, the US FDA granted the product approval to Elekta AB's Elekta Harmony radiation therapy system to deliver radiotherapy in the treatment of various cancers such as lung, prostate, and breast cancers.

Key Takeaways from the Cancer Therapy Market Report Study

• Market size analysis for current cancer therapy market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the cancer therapy market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global cancer therapy market.
• Various opportunities available for the other competitor in the cancer therapy market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current cancer therapy market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for cancer therapy market growth in the coming future?

Target Audience who can be benefited from this Cancer Therapy Market Report Study

• Cancer therapy products providers
• Research organizations and consulting companies
• Cancer therapy -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in cancer therapy
• Various End-users who want to know more about the cancer therapy market and latest technological developments in the cancer therapy market.

Frequently Asked Questions for Cancer Therapy Market:

1. What is Cancer Therapy?

Cancer therapy encompasses all kinds of cancer treatments such as chemotherapy, radiation therapy, hormonal therapy and targeted therapy among others that aim to kill cancer cells to provide therapeutic effect.

2. What is the global market for Cancer Therapy?

Global cancer therapy market was valued at USD 155.23 billion in 2020, growing at a CAGR of 9.12% during the forecast period from 2024 to 2030 to reach USD 266.31 billion by 2030.

3. What are the drivers for Global Cancer Therapy Market?

The cancer therapy market is witnessing a positive market growth owing to the factors such as rising prevalence of cancers which are contributing in the growing demand for cancer treatment, and presence of factors such as increasing aging population wherein age plays a key role in cancer development in certain cancer types such as breast cancer. Moreover, the growing focus on developing targeted therapies to provide a more pronounced therapeutic effect is further driving the cancer therapy market as new products are gaining regulatory approvals for cancer treatment.

4. Who are the key players operating in Global Cancer Therapy Market?

Some of the key market players operating in the cancer therapy market includes GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC,., Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd.and others.

5. Which region has the highest share in Cancer Therapy Market?

North America is expected to hold the highest share in the revenue in the Cancer Therapy market during the forecast period. This can be ascribed to the high prevalence of cancers, and a supportive regulatory environment among other factors in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments are also expected to aid in the cancer therapy market growth in this region.

Table of Contents

1.Cancer Therapy Market Report Introduction

2.Cancer Therapy Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Cancer Therapy Market Key Factors Analysis

• 4.1. Cancer Therapy Market Drivers
  • 4.1.1. Increasing Prevalence of Various Cancers
  • 4.1.2. Rise in External Factors Contributing in Cancer Development
  • 4.1.3. Growing Popularity of Precision Medicine and Targeted Therapy
  • 4.1.4. Technological Advancements in Product Development
• 4.2. Cancer Therapy Market Restraints and Challenges
  • 4.2.1. Potential Side-Effects Associated with Cancer Therapies
  • 4.2.2. High Cost of Cancer Therapies
• 4.3. Cancer Therapy Market Opportunities
  • 4.3.1. Improving Affordability of Cancer Therapies
  • 4.3.2. Development of Safer Cancer Therapies with Minimal Side-Effects

5. Cancer Therapy Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Cancer Therapy Market

7. Cancer Therapy Market Layout

• 7.1. By Therapy Type
  • 7.1.1. Chemotherapy
  • 7.1.2. Radiation Therapy
  • 7.1.3. Hormonal Therapy
  • 7.1.4. Targeted Therapy
  • 7.1.5. Others
• 7.2. By Cancer Type
  • 7.2.1. Breast Cancer
  • 7.2.2. Lung Cancer
  • 7.2.3. Prostate Cancer
  • 7.2.4. Blood Cancers
  • 7.2.5. Others
• 7.3. By End User
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. North America Cancer Therapy Market, by Therapy Type
    • 7.4.1.2. North America Cancer Therapy Market, by Cancer Type
    • 7.4.1.3. North America Cancer Therapy Market, by End User
    • 7.4.1.4. North America Cancer Therapy Market, by Country
    • 7.4.1.4.1. United States
    • 7.4.1.4.2. Canada
    • 7.4.1.4.3. Mexico
  • 7.4.2. Europe
    • 7.4.2.1. Europe Cancer Therapy Market, by Therapy Type
    • 7.4.2.2. Europe Cancer Therapy Market, by Cancer Type
    • 7.4.2.3. Europe Cancer Therapy Market, by End User
    • 7.4.2.4. Europe Cancer Therapy Market, by Country
    • 7.4.2.4.1. France
    • 7.4.2.4.2. Germany
    • 7.4.2.4.3. United Kingdom
    • 7.4.2.4.4. Italy
    • 7.4.2.4.5. Spain
    • 7.4.2.2.6. Russia
    • 7.4.2.2.7. Rest of Europe
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. Asia-Pacific Cancer Therapy Market, by Therapy Type
    • 7.4.3.2. Asia-Pacific Cancer Therapy Market, by Cancer Type
    • 7.4.3.3. Asia-Pacific Cancer Therapy Market, by End User
    • 7.4.3.4. Asia-Pacific Cancer Therapy Market, by Country
    • 7.4.3.4.1. China
    • 7.4.3.4.2. Japan
    • 7.4.3.4.3. India
    • 7.4.3.4.4. Australia
    • 7.4.3.4.5. South Korea
    • 7.4.3.4.6. Rest of Asia Pacific
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. RoW Cancer Therapy Market, by Therapy Type
    • 7.4.4.2. RoW Cancer Therapy Market, by Cancer Type
    • 7.4.4.3. RoW Cancer Therapy Market, by End User
    • 7.4.4.4. RoW Cancer Therapy Market, by Region
    • 7.4.4.4.1. Middle East
    • 7.4.4.4.2. Africa
    • 7.4.4.4.3. South America

8. Cancer Therapy Market Global Company Share Analysis - Key 3-5 Companies

9. Cancer Therapy Market Company and Product Profiles

• 9.1. GlaxoSmithKline
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Eli Lilly & Company
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. F. Hoffmann-La Roche Ltd,
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. AbbVie Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Amgen Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Sanofi
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Merck & Co., Inc.
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Novartis AG
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Pfizer Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. AstraZeneca
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Bristol Myers Squibbs
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Gilead Sciences, Inc.
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Janssen Global Services, LLC
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Elekta AB
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Varian Medical Systems, Inc (Siemens Healthineers AG)
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. Accuray Incorporated
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Pyrexar Medical
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Eckert & Ziegler
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. IBA
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. Panacea Medical Technologies Pvt. Ltd
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us